Skip to main content

Achieve Life Sciences, Inc.

QUIT
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
SEC CIK
0000949858

No open-market purchases or sales by Achieve Life Sciences, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q3 2026; no superinvestor holds it.

Other share classesACHV

Key figures

Market capClose on Nov 20, 2026
$611.8M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026
0
13F valueReported value at the end of Q3 2026
$0
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$54.6M
No comparable prior period
Free cash flow, FY2025
-$49.5M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Superinvestors holding QUIT, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding QUIT at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Achieve Life Sciences, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 21, 2026 (view filing)4:30 PM ETAug 192 daysStewart Richard AlistairDirectorSSale−20.6K$8.49−$175.2K−9.0%208.2K after
Sep 22, 2025 (view filing)Sep 184 daysOki Mark KChief Financial OfficerSSale−50.1K$2.92−$146.2K−28.1%127.9K after
Sep 22, 2025 (view filing)Sep 184 daysStewart Richard AlistairChief Executive OfficerSSale−129.5K$2.92−$378.1K−36.1%228.9K after
Sep 8, 2025 (view filing)Sep 44 daysWan JerryPrincipal Accounting OfficerSSale−14.1K$2.77−$39.0K−30.1%32.7K after
Sep 8, 2025 (view filing)Sep 44 daysKing Thomas BraxtonDirectorSSale−139.9K$2.77−$387.4K−30.7%315.1K after
Sep 8, 2025 (view filing)Sep 44 daysJacobs CindyPresident & CMOSSale−27.6K$2.77−$76.5K−19.3%115.6K after
Sep 8, 2025 (view filing)Sep 44 daysXinos JaimeChief Commercial OfficerSSale−20.9K$2.77−$57.8K−21.9%74.4K after
Mar 19, 2025 (view filing)Mar 172 daysOki Mark KChief Financial OfficerPPurchase+10.0K$2.89+$28.9KNew position10.0K after
Mar 19, 2025 (view filing)Mar 172 daysStewart Richard AlistairChieve Executive OfficerPPurchase+10.0K$2.86+$28.6K+19.7%60.9K after
Mar 6, 2024 (view filing)Mar 42 daysStewart Richard AlistairExecutive ChairmanPPurchase+10.0K$4.59+$45.9K+35.1%38.5K after

Top 10 13F holders, Q3 2026

View all: Top 10 13F holders, Q3 2026

The largest institutional positions in Achieve Life Sciences, Inc. at the end of Q3 2026; share changes are against Q2 2026.

No institution reported holding QUIT in 13F filings for Q3 2026.